- CEO
- Shu Xiang Li
- Full Time Employees
- 2,731
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- No. 221 Huanghai Road Tianjin TI China 300457
- IPO Date
- Jun 18, 2001
- Business
- Tianjin Tianyao Pharmaceuticals Co., Ltd. (600488.SS) engages in the research, development, production and sales of corticosteroids and amino acid active pharmaceutical ingredients (APIs) and finished dosage forms; its core products include corticosteroid APIs such as dexamethasone, prednisone, methylprednisolone and betamethasone series, as well as amino acid APIs like glycine, L-aspartic acid, L-glutamic acid, L-isoleucine, L-leucine and L-lysine acetate; dosage forms encompass injections, ointments, creams, hard capsules, pills, freeze-dried powder injections, inhalation preparations, tablets, infusions and eye drops. The company operates production bases in Tianjin Binhai New Area, Xiangyang in Hubei Province and Yong Guang in Hebei Province, exporting to the United States, Southeast Asia, Europe, South America, Africa and other international markets; it serves hospitals, clinics and pharmacies with products for chronic and acute care in therapeutic areas including emergency rescue drugs, steroid hormones and biologics. Founded in 1939 and headquartered at No. 109, Bawei Road, Hedong District, Tianjin, China, the company functions as a subsidiary of Tianjin Pharmaceutical Group Co., Ltd. and maintains a workforce of approximately 2,884 employees with advanced quality systems including FDA certification for select sterile steroid hormone preparations. Recent developments include the establishment of an Innovation Research Institute in 2024 to advance innovative drug design, discovery and incubation, with early-stage projects like JYSW003 targeting psoriasis showing promising efficacy; the company reports eight new product approvals, 13 consistency evaluations and five FDA-certified products in recent years, alongside ongoing international cooperation such as with Pfizer. For the nine months ended September 30, 2025, it posted sales of CNY 2.23 billion and net income of CNY 69.54 million, reflecting strategic focus on product pipeline diversification, CDMO capabilities and high-value therapeutics.